A Randomized, Double-blind, Placebo-controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Latest Information Update: 17 Nov 2025
At a glance
- Drugs Emugrobart (Primary) ; Tirzepatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms GYMINDA
- Sponsors Roche
Most Recent Events
- 12 Nov 2025 Planned End Date changed from 20 Sep 2027 to 24 Jul 2027.
- 12 Nov 2025 Planned primary completion date changed from 23 Oct 2026 to 21 Aug 2026.
- 12 Nov 2025 Status changed from recruiting to active, no longer recruiting.